



FOR IMMEDIATE RELEASE

Contact: Udo Mattern  
M et P® Pharma AG  
Schynweg 7  
6376 Emmetten  
Switzerland  
Phone: +41-41-618 30 30  
Email: [info@mattern-pharma.com](mailto:info@mattern-pharma.com)

## Biotech takes the path over the nose

- The nasal drug delivery platform of M et P® Pharma addresses unmet needs for managing CNS disorders.
- M et P® Pharma signs exploratory study with Biotech company.

[Emmetten, Switzerland, May 28, 2018] M et P® Pharma AG has entered into a cooperation with a Biotech company in which M et P® will apply its proprietary technology platform ("Silcum®") for nose-to-brain delivery of drugs.

In the light of this new partnership Udo Mattern, CEO of MetP®, says: "This agreement is an important step in M et P®'s continuous ambition of providing sophisticated innovations for the treatment of neurologic diseases."

The nasal route provides a major opportunity for non-invasive delivery of compounds to treat Central Nervous System (CNS) diseases via the systemic circulation and/or by mechanisms that cross directly into the brain and spinal cord via integrated nerve pathways available in the nasal cavity.

In this context, M et P® Pharma AG has developed a unique nasal delivery system for neurotherapeutics. It achieves consistent and high brain availability of drugs and is convenient for patients.

\*\*\*

If you would like more information about this topic, please call Udo Mattern at +41-41-618 30 30, or email [info@mattern-pharma.com](mailto:info@mattern-pharma.com).